Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition

Journal of Molecular and Cellular Cardiology

Volumn 32, Issue 4, 2000, Pages 697-709

  Lim, Hae W ^a   De Windt, Leon J ^a   Mante, Janice ^a   Kimball, Thomas R ^a   Witt, Sandra A ^a   Sussman, Mark A ^a   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Calcineurin; Cyclosporin; Dilated myopathy; Gene Expression; Hypertrophy

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HEART DILATATION; HEART VENTRICLE REMODELING; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0033846104     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2000.1113     Document Type: Article

References (38)

1. Sudden death in the competitve athlete
2. Prevalence of hypertrophic cardiomyopathy in a general population of young adults
3. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
4. Contractile protein mutation and heart disease
5. Familial hypertrophic cardiomyopathy: A genetic model of cardiac hypertrophy
6. Molecular mechanisms regulating the myofilament response to Ca2+: Implications of mutations causal for familial hypertrophic cardiomyopathy
7. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
8. Differential activation of transcription factors induced by Ca2+ response amplitude and duration
9. Calcium oscillations increase the efficiency and specificity of gene expression
10. Alterations in calcium handling in cardiac hypertrophy and heart failure
11. Prevention of cardiac hypertrophy in mice by calcineurin inhibition
12. Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice
13. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop)
14. Stretch-induced increase of resting intracellular calcium concentration in single guinea-pig ventricular myocytes
15. Effect of stretch on contraction and the Ca2+ transient in ferret ventricular muscles during hypoxia and acidosis
16. Diastolic dysfunction and altered energetics in the αMHC(403/+) mouse model of familial hypertrophic cardiomyopathy
17. Effects of left ventricular hypertrophy on force and Ca2+ handling in isolated rat myocardium
18. Pathogenesis of dilated cardiomyopathy: Molecular, structural, and population analysis in tropomodulin-overexpressing transgenic mice
19. Ca2+/calmodulin-independent activation of calcineurin from Dictyostelium by unsaturated long chain fatty acids
20. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons
21. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes
22. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin
23. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy
24. Reversal of left ventricular hypertrophy in hypertensiv patients. A metaanalysis of 109 treatment studies
25. Reversal of hypertrophy: An active biologic process
26. Pathophysiology of heart failure: Changing perceptions
27. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin
28. Calcineurin inhibition and cardiac hypertrophy
29. Calcineurin and cardiac hypertrophy
30. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats
31. Cyclosporine attenuates presure overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure
32. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways
33. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy
34. Calcineurin expression, activation, and function in cardiac pressure overload hypertrophy
35. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation
36. Quantitating immunosuppression
37. Calcineurin and human heart failure
38. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine